Molecular screening of multidrug-resistance tuberculosis by a designated public health laboratory in Taiwan

H.-C. Lin1,2, C.-L. Perng2, Y.-W. Lai2, F.-G. Lin3, C.-J. Chiang4, H.-A. Lin5, R. Jou6,7, T.-S. Chiueh1,2,8
1Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Republic of China
2Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, Taipei, Republic of China
3School of Public Health, National Defense Medical Center, Taipei, Republic of China
4Chest Hospital, Ministry of Health and Welfare, Tainan, Republic of China
5Division of Infection, Department of Medicine, Tri-Service General Hospital SongShan Branch, Taipei, Republic of China
6Tuberculosis Research Center, Taiwan Centers for Disease Control, Taipei, Republic of China
7Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Republic of China
8Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, TaoYuan City, Republic of China

Tóm tắt

This manuscript describes our experience in early identifying MDR-TB cases in high-risk populations by setting up a single-referral molecular diagnosis laboratory in Taiwan. Taiwan Centers for Disease Control designated a single-referral laboratory to provide the GenoType MTBDRplus test for screening high-risk MDR-TB populations nationwide in 2012–2015. A total of 5,838 sputum specimens from 3,308 patients were tested within 3 days turnaround time. Compared with the conventional culture and drug susceptibility testing, the overall performance of the GenoType MTBDRplus test for detecting TB infection showed accuracy of 70.7%, sensitivity of 85.9%, specificity of 65.7%, positive predictive value of 45.5%, and negative predictive value of 93.3%. And the accuracy of detecting rifampin (RIF) resistance, isoniazid (INH) resistance, and MDR-TB (resistant to at least RIF and INH) were 96.5%, 95.2%, and 97.7%, respectively. MDR-TB contacts presented a higher rate of mutated codons 513–519, GenoType MTBDRplus banding pattern: rpoB WT3(−), and rpoB WT4(−) than the treatment failure group. The MDR-TB contact group also had a higher rate of inhA C15T mutation, banding pattern: inhA WT1(−), and inhA MUT1(+) than the recurrent group. Resistance profiles of MDR-TB isolates also varied geographically. The referral molecular diagnosis system contributed to rapid detection and initiation of appropriate therapy.

Tài liệu tham khảo

Chan PC, Chen CH, Chang FY (2014) Extended review of the National Tuberculosis Program and the development of strategy and targets post 2015 in Taiwan. J Formos Med Assoc 113:775–777 Bloch AB, Cauthen GM, Onorato IM, Dansbury KG, Kelly GD, Driver CR, Snider DE Jr (1994) Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271:665–671 Yu CC, Chang CY, Liu CE, Shih LF, Hsiao JH, Chen CH (2010) Drug resistance pattern of mycobacterium tuberculosis complex at a medical center in central Taiwan, 2003-2007. J Microbiol Immunol Infect 43:285–290 Chang CW, Wu MH, Chuang PC, Jou R (2011) Characteristics of multidrug-resistant mycobacterium tuberculosis in Taiwan: a population-based study. Infect Genet Evol 11:633–639 Su WJ (2008) Extensively drug-resistant tuberculosis (XDR-TB) raises challenges in TB control in Taiwan. J Formos Med Assoc 107:827–829 Yu MC, Wu MH, Jou R (2008) Extensively drug-resistant tuberculosis, Taiwan. Emerg Infect Dis 14:849–850 Centers for Disease Control ROCT (2011) Taiwan Tuberculosis Control Report, 2011. Ministry of Health and Welfare, Taiwan Yu MC, Chen HY, Chien SH, Jou R (2015) An integrated management program for MDR-TB results in favourable outcomes in northern Taiwan. Eur Respir J 45:272–275 Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W (2010) Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant mycobacterium tuberculosis complex isolates. J Clin Microbiol 48:1683–1689 Kliiman K, Altraja A (2009) Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 33:1085–1094 Musser JM (1995) Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 8:496–514 Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD (1996) Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 173:196–202 Huang WL, Chen HY, Kuo YM, Jou R (2009) Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant mycobacterium tuberculosis. J Clin Microbiol 47:2520–2524 Lin YH, Tai CH, Li CR, Lin CF, Shi ZY (2013) Resistance profiles and rpoB gene mutations of mycobacterium tuberculosis isolates in Taiwan. J Microbiol Immunol Infect 46:266–270 Tseng ST, Tai CH, Li CR, Lin CF, Shi ZY (2015) The mutations of katG and inhA genes of isoniazid-resistant mycobacterium tuberculosis isolates in Taiwan. J Microbiol Immunol Infect 48:249–255 Stop TB Partnership WHO (2006) Global Plan to Stop TB, 2006–2015. WHO. Available from: WHO/HTB/STB/2006 Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG (1998) Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544 Akpaka PE, Baboolal S, Clarke D, Francis L, Rastogi N (2008) Evaluation of methods for rapid detection of resistance to isoniazid and rifampin in mycobacterium tuberculosis isolates collected in the Caribbean. J Clin Microbiol 46:3426–3428 Barnard M, Albert H, Coetzee G, O’Brien R, Bosman ME (2008) Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 177:787–792 Ong DC, Yam WC, Siu GK, Lee AS (2010) Rapid detection of rifampicin- and isoniazid-resistant mycobacterium tuberculosis by high-resolution melting analysis. J Clin Microbiol 48:1047–1054 Pang Y, Zhou Y, Wang S, Lu J, Lu B, He G, Wang L, Zhao Y (2011) A novel method based on high resolution melting (HRM) analysis for MIRU-VNTR genotyping of mycobacterium tuberculosis. J Microbiol Methods 86:291–297 Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D (2010) Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 48:2495–2501 Causse M, Ruiz P, Gutierrez JB, Zerolo J, Casal M (2008) Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of mycobacterium tuberculosis. Int J Tuberc Lung Dis 12:1456–1460 Hillemann D, Rüsch-Gerdes S, Richter E (2007) Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45:2635–2640 WHO (1998) Laboratory services in tuberculosis contol. Culture Part III. WHO, Geneva. Available from: WHO/TB/98.258 Aung WW, Ei PW, Nyunt WW, Swe TL, Lwin T, Htwe MM, Kim KJ, Lee JS, Kim CK, Cho SN, Song SD, Chang CL (2015) Phenotypic and genotypic analysis of anti-tuberculosis drug resistance in mycobacterium tuberculosis isolates in Myanmar. Ann Lab Med 35:494–499 WHO (2003). Guidelines for surveillance of drug resistance in tuberculosis. WHO/CDS/CSR/RMD/2003. WHO, GENEVA. Available from: http://whqlibdoc.who.int/publications/2003/9241546336.pdf Centers for disease control (2013) Taiwan Guidelines for TB Diagnosis and Treatment. 5th Ed. Ministry of Health and Welfare, Taiwan Sun Y, Harley D, Vally H, Sleigh A (2015) Comparison of characteristics and mortality in multidrug resistant (MDR) and non-MDR tuberculosis patients in China. BMC Public Health 15:1027–1034 Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Rosés S, Maldonado J, Domínguez J (2008) GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 46:3660–3667 Lyu J, Kim MN, Song JW, Choi CM, Oh YM, Lee SD, Kim WS, Kim DS, Shim TS (2013) GenoType(R) MTBDRplus assay detection of drug-resistant tuberculosis in routine practice in Korea. Int J Tuberc Lung Dis 17:120–124 Miotto P, Piana F, Penati V, Canducci F, Migliori GB, Cirillo DM (2006) Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in mycobacterium tuberculosis clinical strains isolated in Italy. J Clin Microbiol 44:2485–2491 Singhal R, Myneedu VP, Arora J, Singh N, Bhalla M, Verma A (2015) Sarin R (2015) early detection of multi-drug resistance and common mutations in mycobacterium tuberculosis isolates from Delhi using GenoType MTBDRplus assay. Indian J Med Microbiol 33(Suppl):46–52 Luetkemeyer AF, Kendall MA, Wu X, Lourenço MC, Jentsch U, Swindells S, Qasba SS, Sanchez J, Havlir DV, Grinsztejn B, Sanne IM, Firnhaber C, Adult AIDS Clinical Trials Group A5255 Study Team (2014) Evaluation of two line probe assays for rapid detection of mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol 52:1052–1059 Lee YS, Kang HR, Lee SH, Kim Y, Kim MY, Shin JH, Moon JY, Lee HK, Park SY, Mo EK, Park YB, Moon SY, Oh M, Ko Y (2016) Diagnostic usefulness of the GenoType MTBDRplus assay for detecting drug-resistant tuberculosis using AFB smear-negative specimens with positive TB-PCR result. Infect Dis (Lond) 48:350–355 Ignatyeva O, Balabanova Y, Nikolayevskyy V, Koshkarova E, Radiulyte B, Davidaviciene E, Riekstina V, Jaama K, Danilovits M, Popa CM, Drobniewski FA (2015) Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries. Tuberculosis 95:581–588 Tolani MP, D’Souza DTB, Mistry NF (2012) Drug resistance mutations and heteroresistance detected using the genotype MTBDRplus assay and their implications for treatment outcomes in patients from Mumbai, India. BMC Infect Dis 12:9–16 Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AMV, Satyanarayana S, Parmar M, Moonan PK, Lo TQ (2015) Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB center in India. PLoS One 10:e0135802